Giving block in the shoulder region to provide better and prolonged pain relief

Not yet recruiting

Conditions: ASA I & ASA II undergoing elective upper limb surgeries

Registration Number: CTRI/2020/06/025889

Lead Sponsor: Pondicherry Institute of medical science

Brief Summary: Ropivacaine is a long-acting regionalanesthetic that is structurally related to bupivacaine. It is a S(âˆ’)enantiomer, unlike bupivacaine, which is a racemate and well-established long-acting regionalanesthetic, which like all amide anesthetics has been associated withcardiotoxicity when used in high concentration or when accidentallyadministered intravascularly. Hence ropivacaine was developed for the purposeof reducing potential toxicity and improving relative sensory and motor blockprofiles. Various adjuvants have been added to local anesthetics in brachialplexus block to achieve quick, dense, and prolonged block; however, the resultsare either inconclusive or associated with side effects.

Nalbuphine, a derivative of14-hydroxymorphine, is an agonist-antagonist opioid acting on Âµ (mu) receptorsas antagonist and Îº (kappa) receptors as agonist with an analgesic potencyequal to morphine and its antagonistic potency is approximately Â¼th ofthat of naloxone. Unlike morphine, it exhibits a ceiling effect on respiratorydepression. Nalbuphine has the potential to maintain or even enhanceÂµ-opioid-based analgesia while simultaneously mitigating the Âµ-opioid sideeffects.Therefore the purpose of this study is to compare by adding nalbuphine withropivacaine in supraclavicular brachial plexus block and to know its efficacy.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: Not specified

Target Recruitment: 70

Inclusion Criteria

American Society Of Anesthesiologists (ASA) Physical Status I To II Of Both Gender Age Between 18 And 60 Years Body Mass Index (BMI) <25 Kg/M2 Elective forearm and hand surgeries in orthopedic and plastic surgeries.

Exclusion Criteria

Allergy to local anesthetics or Nalbuphine Infection at the injection site Patients with clinically significant coagulopathy Preexisting neuromuscular disorders Severe cardiovascular, or pulmonary disease, renal or hepatic disorder Pregnancy and lactation Patients taking medications with opioid or receiving chronic analgesic therapy other than simple analgesics were excluded from the study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare the duration of analgesia between ropivacaine and ropivacaine with nalbuphine for supraclavicular brachial plexus blockade	after complete sensory blockade

Secondary Outcome Measures

Name	Time	Method
To measure the onset of sensory and motor blockade and	To measure the duration motor blockade between the two study groups

Trial Locations

Locations (1): PONDICHERRY INSTITUTE OF MEDICAL SCIENCES
🇮🇳
Pondicherry, PONDICHERRY, India
PONDICHERRY INSTITUTE OF MEDICAL SCIENCES
🇮🇳Pondicherry, PONDICHERRY, India
Arish
Principal investigator
9791853400
thebeast11.bt@gmail.com